Skip to main content
. Author manuscript; available in PMC: 2024 Sep 25.
Published in final edited form as: Cancer. 2023 Nov 29;130(7):1052–1060. doi: 10.1002/cncr.35136

Table 2.

Clinicopathologic features of females with HR+HER2- non-metastatic invasive breast cancer and 1–3 positive sentinel lymph nodes without high-risk features who underwent upfront surgery and completion axillary lymph node dissection.

Overall Number of positive sentinel lymph nodes p
1 2 3
n 1,762 1,159 419 184
Pathologic Tumor Size (mm) 22.0 ± 10.2 21.2 ± 10.0 23.2 ± 10.2 24.3 ± 11.0 <0.001
Pathologic Tumor Stage
T1 857 (48.6) 603 (52.0) 180 (43.0) 74 (40.2) 0.001
T2 883 (50.1) 544 (46.9) 235 (56.1) 104 (56.5)
T3/4 22 (1.2) * * *
Tumor Grade
1 430 (24.4) 293 (25.3) 94 (22.4) 43 (23.4) 0.48
2 1332 (75.6) 866 (74.7) 325 (77.6) 141 (76.6)
Lymphovascular Invasion
Absent 983 (55.8) 680 (58.7) 218 (52.0) 85 (46.2) <0.001
Present 591 (33.5) 354 (30.5) 153 (36.5) 84 (45.7)
Unknown 188 (10.7) 125 (10.8) 48 (11.5) 15 (8.2)
Estrogen Receptor
Positive 1,760 (99.9) * * * 0.06
Negative/Unknown 1 (0.1) * * *
Progesterone Receptor
Positive 1,647 (93.5) 1075 (92.8) 399 (95.2) 173 (94.0) 0.20
Negative/Unknown 115 (6.5) 84 (7.2) 20 (4.8) 11 (6.0)
Breast Surgery
Partial Mastectomy 623 (35.4) 407 (35.1) 146 (34.8) 70 (38.0) 0.72
Mastectomy 1,139 (64.6) 752 (64.9) 273 (65.2) 114 (62.0)
Number of SLN removed 3.3 ± 3.4 2.8 ± 3.0 4.0 ± 3.9 4.9 ± 3.2 <0.001
Number of total LN removed 12.3 ± 7.6 11.3 ± 7.3 13.6 ± 7.8 15.8 ± 10.0 <0.001
Number of total positive LN 2.6 ± 3.0 1.9 ± 2.4 3.4 ± 3.1 5.3 ± 3.8 <0.001

Abbreviations: SLN: sentinel lymph nodes; LN: total lymph nodes

*

Results suppressed: NCDB does not permit aggregate results for cell sizes < 10

Note: Table cells show frequency (column percent) or mean ± standard deviation. No differences were seen when comparing demographic information between the cohorts, and are therefore not shown.